Return to List
Results 1–13 of 13
Title Date
1.

Solutions for Surgical Preparation of the Vagina

Number 571

ABSTRACT: Currently, only povidone-iodine preparations are approved for vaginal surgical-site antisepsis. However, there are compelling reasons to consider chlorhexidine gluconate solutions for off-l...

September 2013

PDF Format
2.

Ethical Issues With Vaccination for the Obstetrician–Gynecologist

Number 564

ABSTRACT: Because of the growing importance of infectious disease prevention in the individual patient and the larger community, it is vital that Fellows of the American College of Obstetricians and ...

May 2013

PDF Format
3.

Integrating Immunizations Into Practice

Number 558

ABSTRACT: Given demonstrated vaccine efficacy, safety, and the large potential for prevention of many infectious diseases among adults, newborns, and pregnant women, obstetrician–gynecologists should...

April 2013

PDF Format
4.

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Number 557

ABSTRACT: Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability. After initial asses...

April 2013

PDF Format
5.

Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism

Number 556

ABSTRACT: The development of menopausal symptoms and related disorders, which lead women to seek prescriptions for postmenopausal estrogen therapy and hormone therapy, is a common reason for a patien...

April 2013

PDF Format
6.

Over-the-Counter Access to Oral Contraceptives

Number 544

ABSTRACT: Unintended pregnancy remains a major public health problem in the United States. Access and cost issues are common reasons why women either do not use contraception or have gaps in use. A p...

December 2012

PDF Format
7.

Access to Emergency Contraception

Number 542

ABSTRACT: Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse, sexual assault, or contraceptive failure. Although the ...

November 2012

PDF Format
8.

Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

Number 540

ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested tha...

November 2012

PDF Format
9.

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall...

August 2012

PDF Format
10.

Misoprostol for Postabortion Care

Number 427

ABSTRACT: The World Health Organization estimates that 67,000 women, mostly in developing countries, die each year from untreated or inadequately treated abortion complications. Postabortion care, a ...

February 2009

PDF Format
11.

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2012)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remai...

August 2008

PDF Format
12.

Brand Versus Generic Oral Contraceptives

Number 375

(Reaffirmed 2013)

ABSTRACT:The U.S. Food and Drug Administration considers generic and brand name oral contraceptive (OC) products clinically equivalent and interchangeable. The American College of Obstetricians and G...

August 2007

PDF Format
13.

Tamoxifen and Uterine Cancer

Number 336

(Reaffirmed 2008, Replaces No. 232, April 2000)

ABSTRACT: Tamoxifen may be associated with endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma, and uterine sarcoma. Any symptoms of endometrial hyperplasia or cancer reported...

June 2006

PDF Format